Ryzolt

Ryzolt is a brand name of tramadol, approved by the FDA in the following formulation(s):

RYZOLT (tramadol hydrochloride - tablet, extended release; oral)

• 
  Manufacturer: PURDUE PHARMA
  
  Approval date: December 30, 2008
  
  Strength(s): 100MG ^[RLD][AB2], 200MG ^[AB2], 300MG ^[AB2]

Has a generic version of Ryzolt been approved?

A generic version of Ryzolt has been approved by the FDA. However, this does not mean that the product will necessarily be commercially available - possibly because of drug patents and/or drug exclusivity. The following products are equivalent to Ryzolt and have been approved by the FDA:

tramadol hydrochloride tablet, extended release; oral

• 
  Manufacturer: SUN PHARMA GLOBAL
  
  Approval date: December 30, 2011
  
  Strength(s): 100MG ^[AB2], 200MG ^[AB2], 300MG ^[AB2]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Ryzolt. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Controlled release formulation
  Patent 5,591,452
  Issued: January 7, 1997
  Inventor(s): Miller; Ronald B. & Leslie; Stewart T. & Malkowska; Sandra T. A. & Smith; Kevin J. & Wimmer; Walter & Winkler; Horst & Hahn; Udo & Prater; Derek A.
  Assignee(s): Euro-Celtique, S.A.
  A controlled release preparation for oral administration contains tramadol, or a pharmaceutically acceptable salt thereof, as active ingredient.
  
  Patent expiration dates:
  
  
  • May 10, 2014
    
    ✓ 
    Drug product
  
  



• 
  Controlled release tramadol
  Patent 6,254,887
  Issued: July 3, 2001
  Inventor(s): Miller; Ronald Brown & Leslie; Stewart Thomas & Malkowska; Sandra Therese Antoinette & Smith; Kevin John & Wimmer; Walter & Winkler; Horst & Hahn; Udo & Prater; Derek Allan
  Assignee(s): Euro-Celtique S.A.
  A controlled release preparation for oral administration contains tramadol, or a pharmaceutically acceptable salt thereof, as active ingredient.
  
  Patent expiration dates:
  
  
  • May 10, 2014
    
    ✓ 
    Drug product
  
  



• 
  Cross-linked high amylose starch for use in controlled-release pharmaceutical formulations and processes for its manufacture
  Patent 6,607,748
  Issued: August 19, 2003
  Inventor(s): Vincent; Lenaerts & Roland Herwig Friedrich; Beck & Elsie; Van Bogaert & Francois; Chouinard & Reiner; Höpcke & Cyril; Désévaux
  The present invention relates to a novel form of cross-linked high amylose starch and processes for its manufacture. Such cross-linked high amylose starch is useful as an excipient in a controlled-release pharmaceutical formulation when compressed with pharmaceutical agent(s) in a tablet. Such cross-linked high amylose starch is prepared by (a) cross-linking and chemical modification of high amylose starch, (b) gelatinization, and (c) drying to obtain a powder of said controlled release excipient. In a preferred embodiment, such cross-linked high amylose starch is prepared in the following steps: (1) granular cross-linking and additional chemical modification (e.g., hydroxypropylation) of high-amylose starch; (2) thermal gelatinization of the starch from step (1); and (3) drying the starch from step (2) to yield a powder capable of being used as a controlled release excipient.
  
  Patent expiration dates:
  
  
  • June 29, 2020
    
    ✓ 
    Drug product
  
  



• 
  Sustained-release tramadol formulations with 24-hour efficacy
  Patent 7,988,998
  Issued: August 2, 2011
  Inventor(s): Lenaerts; Vincent & Ouadji-Nijki; Patricia Laure & Bacon; Jonathan & Ouzérourou; Rachid & Gervais; Sonia & Rahmouni; Miloud & Smith; Damon
  Assignee(s): Labopharm Inc.
  Labopharm Europe Limited
  Labopharm (Barbados) Limited
  A sustained-release tramadol formulation oral administration is provided which, upon initial administration of one dose, provides an analgesic effect within 2 hours, which analgesic effect continues for at least 24 hours after administration.
  
  Patent expiration dates:
  
  
  • October 27, 2023
    
    ✓ 
    Drug product
  
  

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

• Exclusivity expiration dates:
  • December 30, 2011 - NEW PRODUCT
  
  

See also...

• Ryzolt Consumer Information (Drugs.com)
• Ryzolt Extended-Release Tablets Consumer Information (Wolters Kluwer)
• Ryzolt Consumer Information (Cerner Multum)
• Ryzolt Advanced Consumer Information (Micromedex)
• Tramadol Consumer Information (Drugs.com)
• Tramadol Consumer Information (Wolters Kluwer)
• Tramadol Extended-Release Capsules Consumer Information (Wolters Kluwer)
• Tramadol Extended-Release Tablets Consumer Information (Wolters Kluwer)
• Tramadol Orally Disintegrating Tablets Consumer Information (Wolters Kluwer)
• Tramadol Consumer Information (Cerner Multum)
• FusePaq Synapryn Advanced Consumer Information (Micromedex)
• Tramadol Advanced Consumer Information (Micromedex)
• Tramadol Hydrochloride AHFS DI Monographs (ASHP)